0.4575

3.80% -0.0181

Bioline Rx Ltd Adr (BLRX)

Overview News Price History Option Chain Why BLRX Down? Discussions Forecast Stock Split

Bioline Rx Ltd Adr stock is traded at $0.4575, with a volume of 452.76K. It is down -3.80% in the last 24 hours and down -2.64% over the past month. BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Previous Close:

$0.4756

Open:

$0.49

24h Volume:

452.76K

Relative Volume:

1.50

Market Cap:

$38.02M

Revenue:

Net Income/Loss:

$-60.61M

P/E Ratio:

-0.7625

EPS:

-0.6

Net Cash Flow:

$-22.91M

1W Performance:

+2.81%

1M Performance:

-2.64%

6M Performance:

-28.52%

1Y Performance:

-72.93%

1-Day Range:

$0.4435

$0.49

1-Week Range:

$0.4295

$0.49

52-Week Range:

$0.39

$1.89

Bioline Rx Ltd Adr Stock (BLRX) Company Profile

Name

Bioline Rx Ltd Adr

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

Address

Employee

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

BLRX's Discussions on Twitter

Compare BLRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BLRX	0.4577	38.02M	0	-60.61M	-22.91M	-0.60
VRTX	467.20	119.83B	10.63B	-479.80M	-1.35B	13.33
REGN	760.34	83.28B	13.85B	4.65B	3.32B	35.06
ARGX	565.93	33.74B	1.86B	-40.29M	-1.28B	-4.16
ALNY	230.51	30.38B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.13	24.08B	3.30B	-501.07M	1.03B	11.54

Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-18-17	Upgrade	Maxim Group	Hold → Buy
Feb-13-17	Initiated	Rodman & Renshaw	Buy
Aug-12-16	Downgrade	Maxim Group	Buy → Hold
Aug-17-15	Reiterated	Maxim Group	Buy
Jul-27-15	Reiterated	ROTH Capital	Buy
Jun-22-15	Initiated	JMP Securities	Mkt Outperform

View All

Bioline Rx Ltd Adr Stock (BLRX) Latest News

Nov 12, 2024

BioLineRx Granted Extension to Meet Nasdaq Requirements - TipRanks

Nov 12, 2024

Nov 05, 2024

BioLineRx’s Motixafortide Shows Promise in Sickle Cell Trials - TipRanks

Nov 05, 2024

Oct 24, 2024

BioLineRx stock hits 52-week low at $0.39 amid market challenges - Investing.com India

Oct 24, 2024

Oct 16, 2024

BioLineRx Secures Extended U.S. Patent for Motixafortide - TipRanks

Oct 16, 2024

BioLineRx secures US patent for cancer drug motixafortide - Investing.com

Oct 16, 2024

BioLineRx secures US patent for cancer drug motixafortide By Investing.com - Investing.com UK

Oct 16, 2024

Oct 15, 2024

BioLineRx stock hits 52-week low at $0.43 amid market challenges - Investing.com

Oct 15, 2024

Oct 07, 2024

Riding the Waves: A Guide to Investing in BLRX Stock - The InvestChronicle

Oct 07, 2024

Market Insight: Bioline Rx Ltd ADR (BLRX)’s Notable Drop, Closing at 0.46 - The Dwinnex

Oct 07, 2024

Oct 02, 2024

BioLineRx stock hits 52-week low at $0.5 amid market challenges - Investing.com

Oct 02, 2024

Oct 01, 2024

BioLineRx Ltd. Shareholders Approve Key Resolutions - TipRanks

Oct 01, 2024